Related references
Note: Only part of the references are listed.Single-Dose, Placebo-Controlled, Randomized Study of AMG 785, a Sclerostin Monoclonal Antibody
Desmond Padhi et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Regulation of Circulating Sclerostin Levels by Sex Steroids in Women and in Men
Ulrike Il Moedder et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Relation of Age, Gender, and Bone Mass to Circulating Sclerostin Levels in Women and Men
Ulrike I. Moedder et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Determination of Serum and Plasma Sclerostin Concentrations by Enzyme-Linked Immunoassays
Melissa McNulty et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Reference intervals of biochemical bone turnover markers for Saudi Arabian women: A cross-sectional study
Mohammed-Salleh M. Ardawi et al.
BONE (2010)
Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls
A. H. van Lierop et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2010)
Two Doses of Sclerostin Antibody in Cynomolgus Monkeys Increases Bone Formation, Bone Mineral Density, and Bone Strength
Michael S. Ominsky et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Serum Sclerostin Levels Negatively Correlate with Parathyroid Hormone Levels and Free Estrogen Index in Postmenopausal Women
Faryal S. Mirza et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Increased Sclerostin Serum Levels Associated with Bone Formation and Resorption Markers in Patients with Immobilization-Induced Bone Loss
Agostino Gaudio et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
PTH and PTHrP signaling in osteoblasts
Nabanita S. Datta et al.
CELLULAR SIGNALLING (2009)
Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis
Xiaodong Li et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength
Xiaodong Li et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone
G. Silvestrini et al.
JOURNAL OF MOLECULAR HISTOLOGY (2007)
Molecular and cellular mechanisms of the anabolic effect of intermittent PTH
Robert L. Jilka
BONE (2007)
Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: A novel mechanism for hormonal control of osteoblastogenesis
T Bellido et al.
ENDOCRINOLOGY (2005)
SOST is a target gene for PTH in bone
H Keller et al.
BONE (2005)
Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling
XF Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Effects of parathyroidectomy on lead mobilization from bone in patients with primary hyperparathyroidism
W Osterode et al.
BONE (2004)
Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts - A putative explanation for why intermittent administration is needed for bone anabolism
T Bellido et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
DG Winkler et al.
EMBO JOURNAL (2003)
A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population
K Staehling-Hampton et al.
AMERICAN JOURNAL OF MEDICAL GENETICS (2002)
Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease
W Balemans et al.
JOURNAL OF MEDICAL GENETICS (2002)
Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein
ME Brunkow et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2001)